Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Larimar Therapeutics (Nasdaq: LRMR), a clinical-stage biotechnology company, announced that CEO Carole Ben-Maimon will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, 2020, at 1:40 p.m. EDT.
Rhea-AI Summary
Larimar Therapeutics (Nasdaq: LRMR), a clinical-stage biotechnology company, announced that CEO Carole Ben-Maimon will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, 2020, at 1:40 p.m. EDT. The company focuses on developing treatments for complex rare diseases, with its lead compound CTI-1601 currently in Phase 1 clinical trials aimed at addressing Friedreich’s ataxia. Larimar intends to utilize its intracellular delivery platform to create additional fusion proteins targeting other rare diseases.
Positive
- None.
Negative
- None.
Details
News Market Reaction – LRMR
The recorded move for LRMR in the trading session of this news was -6.19%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BALA CYNWYD, Pa., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will virtually present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Monday, September 21, 2020, at 1:40 p.m. EDT.
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Investor Contact:
Mike Celano
Larimar Therapeutics
(215) 327-1838
mcelano@larimartx.com
Media Contact:
Gina Cestari
6 Degrees
(917) 797-7904
gcestari@6degreespr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.